Achieve Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing cytisinicline, a plant-based compound, as a treatment for nicotine dependence, including smoking cessation. The company is pursuing FDA approval for cytisinicline and is exploring its use for additional methods of nicotine dependence beyond smoking. Achieve relies on third-party manufacturers for cytisinicline supply and is focused on commercialization efforts pending regulatory approval.
Q2 FY2026 — expected 2026-09-18
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-24 | 2025-12-31 | 0001193125-26-120690 | EDGAR | 78K words |
| 2025-03-11 | 2024-12-31 | 0000950170-25-036831 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0000950170-24-038049 | EDGAR | — |
| 2023-03-16 | 2022-12-31 | 0001564590-23-003800 | EDGAR | — |
| 2022-03-10 | 2021-12-31 | 0001564590-22-009485 | EDGAR | — |
| 2021-03-11 | 2020-12-31 | 0001564590-21-012523 | EDGAR | — |
| 2020-03-13 | 2019-12-31 | 0001564590-20-010642 | EDGAR | — |
| 2019-03-14 | 2018-12-31 | 0001564590-19-007838 | EDGAR | — |
| 2018-03-01 | 2017-12-31 | 0001564590-18-004159 | EDGAR | — |
| 2017-02-23 | 2016-12-31 | 0001564590-17-002109 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-268074 | EDGAR | 51K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-104571 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0000950170-25-069806 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123375 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096193 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056929 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062028 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0000950170-23-042401 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019680 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001564590-22-037646 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001564590-22-029122 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001564590-22-019876 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-24 | 0001193125-26-120687 | EDGAR | 3K words |
| 2025-11-06 | 0001193125-25-268056 | EDGAR | — |
| 2025-10-07 | 0001193125-25-233581 | EDGAR | — |
| 2025-09-11 | 0001193125-25-201418 | EDGAR | — |
| 2025-08-07 | 0000950170-25-104569 | EDGAR | — |
| 2025-06-27 | 0000950170-25-091055 | EDGAR | — |
| 2025-06-06 | 0000950170-25-083214 | EDGAR | — |
| 2025-05-13 | 0000950170-25-069804 | EDGAR | — |
| 2025-03-11 | 0000950170-25-036830 | EDGAR | — |
| 2025-02-10 | 0000950170-25-017068 | EDGAR | — |
345 total filings indexed. 313 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000949858 |
| Ticker | ACHV |
| Exchange | Nasdaq |
| SIC | 2835: In Vitro & In Vivo Diagnostic Substances |
| Incorporated | DE |
| Website | https://www.achievelifesciences.com |
| Listed | 1995-10-12 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report